Emerging Threats in Antifungal-Resistant Fungal Pathogens

The use of antifungal drugs in the therapy of fungal diseases can lead to the development of antifungal resistance. Resistance has been described for virtually all antifungal agents in diverse pathogens, including Candida and Aspergillus species. The majority of resistance mechanisms have also been elucidated at the molecular level in these pathogens. Drug resistance genes and genome mutations have been identified. Therapeutic choices are limited for the control of fungal diseases, and it is tempting to combine several drugs to achieve better therapeutic efficacy. In the recent years, several novel resistance patterns have been observed, including antifungal resistance originating from environmental sources in Aspergillus fumigatus and the emergence of simultaneous resistance to different antifungal classes (multidrug resistance) in different Candida species. This review will summarize these current trends.

[1]  D. Perlin.  Echinocandin Resistance in Candida. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  D. Sanglard,et al.  Defining the frontiers between antifungal resistance, tolerance and the concept of persistence. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[3]  H. Fan,et al.  First Detection of TR34 L98H and TR46 Y121F T289A Cyp51 Mutations in Aspergillus fumigatus Isolates in the United States , 2015, Journal of Clinical Microbiology.

[4]  D. Sanglard,et al.  Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms , 2015, Antimicrobial Agents and Chemotherapy.

[5]  D. Sanglard,et al.  Acquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy , 2015, Antimicrobial Agents and Chemotherapy.

[6]  M. Arendrup,et al.  Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations. , 2015, The Journal of antimicrobial chemotherapy.

[7]  Erika Shor,et al.  Update on Antifungal Drug Resistance , 2015, Current Clinical Microbiology Reports.

[8]  P. Hauser,et al.  Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus , 2015, Emerging infectious diseases.

[9]  U. Groß,et al.  Environmental Isolates of Azole-Resistant Aspergillus fumigatus in Germany , 2015, Antimicrobial Agents and Chemotherapy.

[10]  David W. Denning,et al.  How to bolster the antifungal pipeline , 2015, Science.

[11]  Kaitlin F. Mitchell,et al.  Community participation in biofilm matrix assembly and function , 2015, Proceedings of the National Academy of Sciences.

[12]  J. Sobel,et al.  Candida glabrata mutator phenotype promotes resistance to multiple antifungal drugs , 2015 .

[13]  Z. Lončar,et al.  Epidemiology of candidaemia in burn-injured patients: A Croatian nine-year study , 2015 .

[14]  U. Himmelreich,et al.  Towards non-invasive differential diagnosis of cryptococcosis: magnetic resonance spectroscopy reveals marker metabolites of cerebral cryptococcomas and cell viability , 2015 .

[15]  J. Donnelly.  Editorial: A new Editor-in-Chief and the 40th anniversary of the Journal of Antimicrobial Chemotherapy. , 2015, The Journal of antimicrobial chemotherapy.

[16]  M. Arendrup,et al.  Echinocandin resistance: an emerging clinical problem? , 2014, Current opinion in infectious diseases.

[17]  D. Kontoyiannis,et al.  Drug-Resistant Candida glabrata Infection in Cancer Patients , 2014, Emerging infectious diseases.

[18]  A. Mitchell,et al.  Fungal biofilms, drug resistance, and recurrent infection. , 2014, Cold Spring Harbor perspectives in medicine.

[19]  T. Calandra,et al.  Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? , 2014, Intensive Care Medicine.

[20]  T. Sorrell,et al.  Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study. , 2014, The Journal of antimicrobial chemotherapy.

[21]  W. Schaffner,et al.  Role of FKS Mutations in Candida glabrata: MIC Values, Echinocandin Resistance, and Multidrug Resistance , 2014, Antimicrobial Agents and Chemotherapy.

[22]  M. Arendrup.  Update on antifungal resistance in Aspergillus and Candida. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[23]  Ronald N. Jones,et al.  Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp. , 2014, Diagnostic microbiology and infectious disease.

[24]  M. Cuenca‐Estrella,et al.  EUCAST Technical Note on Candida and micafungin, anidulafungin and fluconazole , 2014, Mycoses.

[25]  Miguel C. Teixeira,et al.  MFS multidrug transporters in pathogenic fungi: do they have real clinical impact? , 2014, Front. Physiol..

[26]  Andrew J. Nieuwkoop,et al.  Amphotericin forms an extramembranous and fungicidal sterol sponge , 2014, Nature chemical biology.

[27]  A. Fothergill,et al.  Impact of New Antifungal Breakpoints on Antifungal Resistance in Candida Species , 2014, Journal of Clinical Microbiology.

[28]  M. Arendrup,et al.  Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. , 2013, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[29]  K. Lagrou,et al.  Azole resistance in Aspergillus fumigatus: a growing public health concern. , 2013, Current opinion in infectious diseases.

[30]  S. Lindquist,et al.  Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B , 2013, PLoS biology.

[31]  F. V. van Tiel,et al.  Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Christophe d'Enfert,et al.  Candida albicans biofilms: building a heterogeneous, drug-tolerant environment. , 2013, Current opinion in microbiology.

[33]  D. Denning,et al.  The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus. , 2013, The Journal of antimicrobial chemotherapy.

[34]  M. Castanheira,et al.  Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  S. Kelly,et al.  Molecular Mechanisms of Drug Resistance in Clinical Candida Species Isolated from Tunisian Hospitals , 2013, Antimicrobial Agents and Chemotherapy.

[36]  B. Zwaan,et al.  Triazole fungicides and the selection of resistance to medical triazoles in the opportunistic mould Aspergillus fumigatus. , 2013, Pest management science.

[37]  C. Morélot-Panzini,et al.  Unrecognized suffering in the ICU: addressing dyspnea in mechanically ventilated patients , 2013, Intensive Care Medicine.

[38]  David W. Denning,et al.  Hidden Killers: Human Fungal Infections , 2012, Science Translational Medicine.

[39]  S. Magill,et al.  Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  A. Goffeau,et al.  Yeast ATP-binding cassette transporters conferring multidrug resistance. , 2012, Annual review of microbiology.

[41]  P. Le Pape,et al.  Amino acid substitutions in the Candida albicans sterol Δ5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence. , 2012, The Journal of antimicrobial chemotherapy.

[42]  M. Pfaller,et al.  Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012 , 2012, Journal of Clinical Microbiology.

[43]  W. Melchers,et al.  Triazole Fungicides Can Induce Cross-Resistance to Medical Triazoles in Aspergillus fumigatus , 2012, PloS one.

[44]  S. Kelly,et al.  Azole Resistance by Loss of Function of the Sterol Δ5,6-Desaturase Gene (ERG3) in Candida albicans Does Not Necessarily Decrease Virulence , 2012, Antimicrobial Agents and Chemotherapy.

[45]  M. Pfaller,et al.  Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. , 2012, The American journal of medicine.

[46]  Ronald N. Jones,et al.  Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. , 2011, Diagnostic microbiology and infectious disease.

[47]  D. Perlin.  Current perspectives on echinocandin class drugs. , 2011, Future microbiology.

[48]  F. Dromer,et al.  Development of Echinocandin Resistance in Clavispora lusitaniae during Caspofungin Treatment , 2011, Journal of Clinical Microbiology.

[49]  W. Melchers,et al.  Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis? , 2011, Future microbiology.

[50]  S. Katiyar,et al.  Mutational Analysis of Flucytosine Resistance in Candida glabrata , 2010, Antimicrobial Agents and Chemotherapy.

[51]  D. Kelly,et al.  Identification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans , 2010, Antimicrobial Agents and Chemotherapy.

[52]  D. Kelly,et al.  A Clinical Isolate of Candida albicans with Mutations in ERG11 (Encoding Sterol 14α-Demethylase) and ERG5 (Encoding C22 Desaturase) Is Cross Resistant to Azoles and Amphotericin B , 2010, Antimicrobial Agents and Chemotherapy.

[53]  C. d’Enfert,et al.  Interaction of Candida albicans Biofilms with Antifungals: Transcriptional Response and Binding of Antifungals to Beta-Glucans , 2010, Antimicrobial Agents and Chemotherapy.

[54]  Thomas J Walsh,et al.  Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  P. Le Pape,et al.  Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. , 2010, Diagnostic microbiology and infectious disease.

[56]  M. Castanheira,et al.  Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest Methods with the CLSI Broth Microdilution Method for Echinocandin Susceptibility Testing of Candida Species , 2010, Journal of Clinical Microbiology.

[57]  S. Jaffar,et al.  Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  A. Goffeau,et al.  Fungal PDR transporters: Phylogeny, topology, motifs and function. , 2010, Fungal genetics and biology : FG & B.

[59]  D. Brèthes,et al.  Molecular Mechanisms of Resistance to 5-Fluorocytosine in Laboratory Mutants of Candida glabrata , 2010, Mycopathologia.

[60]  A. Driessen,et al.  Phylogenetic analysis of fungal ABC transporters , 2010, BMC Genomics.

[61]  C. Hennequin,et al.  Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrata Bloodstream Isolates Serially Obtained from a Hematopoietic Stem Cell Transplant Recipient , 2009, Antimicrobial Agents and Chemotherapy.

[62]  D. Sanglard,et al.  Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. , 2009, FEMS yeast research.

[63]  M. Pfaller,et al.  Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007 , 2009, Journal of Clinical Microbiology.

[64]  J. J. Coleman,et al.  Efflux in Fungi: La Pièce de Résistance , 2009, PLoS pathogens.

[65]  G. Fadda,et al.  Gain of Function Mutations in CgPDR1 of Candida glabrata Not Only Mediate Antifungal Resistance but Also Enhance Virulence , 2009, PLoS pathogens.

[66]  D. Choudhury,et al.  MFS transportome of the human pathogenic yeast Candida albicans , 2008, BMC Genomics.

[67]  W. Melchers,et al.  Academic Editor: Chris Kibbler, Royal Free Hospital London, United Kingdom , 2007 .

[68]  P. D. Rogers,et al.  Mutations in the multi‐drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole‐resistant Candida albicans strains , 2008, Molecular microbiology.

[69]  F. Dromer,et al.  Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing , 2008, Antimicrobial Agents and Chemotherapy.

[70]  R. Homayouni,et al.  A Gain-of-Function Mutation in the Transcription Factor Upc2p Causes Upregulation of Ergosterol Biosynthesis Genes and Increased Fluconazole Resistance in a Clinical Candida albicans Isolate , 2008, Eukaryotic Cell.

[71]  S. Katiyar,et al.  A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility , 2008, Antimicrobial Agents and Chemotherapy.

[72]  D. Denning,et al.  EUCAST technical note on fluconazole. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[73]  R. Homayouni,et al.  The Transcription Factor Mrr1p Controls Expression of the MDR1 Efflux Pump and Mediates Multidrug Resistance in Candida albicans , 2007, PLoS pathogens.

[74]  Y. Uehara,et al.  Characterization of Three Classes of Membrane Proteins Involved in Fungal Azole Resistance by Functional Hyperexpression in Saccharomyces cerevisiae , 2007, Eukaryotic Cell.

[75]  R. Homayouni,et al.  Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome‐wide expression studies , 2006, Molecular microbiology.

[76]  K. Breunig,et al.  Evolution of gene families: the multidrug resistance transporter genes in five related yeast species. , 2006, FEMS yeast research.

[77]  W. Nierman,et al.  Transcriptome analysis of Aspergillus fumigatus exposed to voriconazole , 2006, Current Genetics.

[78]  J. Berman,et al.  A Mutation in Tac1p, a Transcription Factor Regulating CDR1 and CDR2, Is Coupled With Loss of Heterozygosity at Chromosome 5 to Mediate Antifungal Resistance in Candida albicans , 2006, Genetics.

[79]  M. Laverdière,et al.  Inactivation of Sterol Δ5,6-Desaturase Attenuates Virulence in Candida albicans , 2005, Antimicrobial Agents and Chemotherapy.

[80]  S. A. Parent,et al.  Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates , 2005, Antimicrobial Agents and Chemotherapy.

[81]  C. Selitrennikoff,et al.  Cryptococcus neoformans Resistance to Echinocandins: (1,3)β-Glucan Synthase Activity Is Sensitive to Echinocandins , 2005, Antimicrobial Agents and Chemotherapy.

[82]  E. Mellado,et al.  Differences in Interactions between Azole Drugs Related to Modifications in the 14-α Sterol Demethylase Gene (cyp51A) of Aspergillus fumigatus , 2005, Antimicrobial Agents and Chemotherapy.

[83]  J. Lopez-Ribot,et al.  Candida Biofilms: an Update , 2005, Eukaryotic Cell.

[84]  M. Laverdière,et al.  Inactivation of sterol Delta5,6-desaturase attenuates virulence in Candida albicans. , 2005, Antimicrobial agents and chemotherapy.

[85]  D. Sanglard,et al.  TAC1, Transcriptional Activator of CDR Genes, Is a New Transcription Factor Involved in the Regulation of Candida albicans ABC Transporters CDR1 and CDR2 , 2004, Eukaryotic Cell.

[86]  L. Tabernero,et al.  Molecular Mechanisms of Primary Resistance to Flucytosine in Candida albicans , 2004, Antimicrobial Agents and Chemotherapy.

[87]  R. Wenzel,et al.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[88]  D. Soll,et al.  Clade-Specific Flucytosine Resistance Is Due to a Single Nucleotide Change in the FUR1 Gene of Candida albicans , 2004, Antimicrobial Agents and Chemotherapy.

[89]  E. Mellado,et al.  A Point Mutation in the 14α-Sterol Demethylase Gene cyp51A Contributes to Itraconazole Resistance in Aspergillus fumigatus , 2004, Antimicrobial Agents and Chemotherapy.

[90]  S. Kelly,et al.  Investigation into the molecular mechanisms of itraconazole resistance in Candida dubliniensis , 2003 .

[91]  D. Sanglard,et al.  Candida albicans Mutations in the Ergosterol Biosynthetic Pathway and Resistance to Several Antifungal Agents , 2003, Antimicrobial Agents and Chemotherapy.

[92]  M. Pfaller,et al.  Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location , 2003, Journal of Clinical Microbiology.

[93]  G. Goldman,et al.  Multiple Resistance Mechanisms among Aspergillus fumigatus Mutants with High-Level Resistance to Itraconazole , 2003, Antimicrobial Agents and Chemotherapy.

[94]  D. Denning,et al.  Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. , 2002, Fungal genetics and biology : FG & B.

[95]  H. Yamaguchi,et al.  A Novel Mechanism of Fluconazole Resistance Associated with Fluconazole Sequestration in Candida albicans Isolates from a Myelofibrosis Patient , 2002, Microbiology and immunology.

[96]  M. Bard,et al.  Candida albicans Sterol C-14 Reductase, Encoded by the ERG24 Gene, as a Potential Antifungal Target Site , 2002, Antimicrobial Agents and Chemotherapy.

[97]  D. Sanglard,et al.  Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. , 2002, The Lancet. Infectious diseases.

[98]  A. Casadevall,et al.  The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. , 2000, The Journal of infectious diseases.

[99]  D. Sanglard,et al.  A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole. , 2000, Microbiology.

[100]  A. Espinel-Ingroff,et al.  Correlation of Fluconazole MICs with Clinical Outcome in Cryptococcal Infection , 2000, Antimicrobial Agents and Chemotherapy.

[101]  M. Ghannoum,et al.  An evaluation of the in vitro activity of terbinafine. , 2000, Medical mycology.

[102]  T. C. White,et al.  The R467K Amino Acid Substitution in Candida albicans Sterol 14α-Demethylase Causes Drug Resistance through Reduced Affinity , 2000, Antimicrobial Agents and Chemotherapy.

[103]  M H Saier,et al.  Unified inventory of established and putative transporters encoded within the complete genome of Saccharomyces cerevisiae , 1998, FEBS letters.

[104]  M. Bard,et al.  Sequencing, Disruption, and Characterization of the Candida albicans Sterol Methyltransferase (ERG6) Gene: Drug Susceptibility Studies in erg6 Mutants , 1998, Antimicrobial Agents and Chemotherapy.

[105]  K. Kuchler,et al.  Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters , 1995, Antimicrobial agents and chemotherapy.

[106]  D. Kelly,et al.  Mode of Action and Resistance to Azole Antifungals Associated with the Formation of 14α-Methylergosta-8,24(28)-dien-3β,6α-diol , 1995 .